Cited 22 times in
Analysis of hydrolyzable polyethylene glycol hydrogels and deproteinized bone mineral as delivery systems for glycosylated and non-glycosylated bone morphogenetic protein-2
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정의원 | - |
dc.contributor.author | 조규성 | - |
dc.date.accessioned | 2014-12-19T16:20:41Z | - |
dc.date.available | 2014-12-19T16:20:41Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1742-7061 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89352 | - |
dc.description.abstract | Bone morphogenetic proteins (BMP), in particular BMP-2, are the growth factors primarily responsible for osteoinduction. A knowledge of interactions between bone substitute materials and growth factor variants is crucial to designing bone substitutes with an ideal release profile. Here we compare glycosylated and non-glycosylated recombinant human bone morphogenetic protein-2 (rhBMP-2) either incorporated into a hydrolyzable polyethylene glycol (PEG) hydrogel developed as a slow release system or adsorbed to a deproteinized bovine bone matrix (DBBM), a clinically well-established bone substitute material. rhBMP-2 loaded materials were immersed in cell culture medium and rhBMP-2 concentration profiles in the supernatant were determined by an enzyme-linked immunosorbent assay. The corresponding biological activities were assessed in vitro by alkaline phosphatase activity assay. We show a strong affinity of rhBMP-2 for DBBM and reduced biological activity after its release from PEG hydrogels. Glycosylated rhBMP-2 was significantly less affected by the hydrogel and interacted significantly more strongly with DBBM than non-glycosylated rhBMP-2. We therefore question the combination of PEG hydrogels with DBBM as a rhBMP-2 delivery system over DBBM alone, since rhBMP-2 released from the hydrogel will be trapped by DBBM. Moreover, our results suggest that glycosylated rhBMP-2 is favorable in combination with PEG hydrogels, since its activity is better preserved, whereas in combination with DBBM non-glycosylated rhBMP-2 is favorable, benefiting from an initially higher concentration of free rhBMP-2. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ACTA BIOMATERIALIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/administration & dosage* | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/chemistry | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/genetics | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/metabolism* | - |
dc.subject.MESH | Bone and Bones/chemistry* | - |
dc.subject.MESH | Cattle | - |
dc.subject.MESH | Cell Line | - |
dc.subject.MESH | Cell Survival | - |
dc.subject.MESH | Drug Carriers/chemistry | - |
dc.subject.MESH | Drug Carriers/metabolism* | - |
dc.subject.MESH | Drug Delivery Systems* | - |
dc.subject.MESH | Glycosylation | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydrogels/chemistry | - |
dc.subject.MESH | Hydrogels/metabolism* | - |
dc.subject.MESH | Hydrolysis | - |
dc.subject.MESH | Materials Testing | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Polyethylene Glycols/chemistry | - |
dc.subject.MESH | Polyethylene Glycols/metabolism* | - |
dc.subject.MESH | Recombinant Proteins/administration & dosage | - |
dc.subject.MESH | Recombinant Proteins/chemistry | - |
dc.subject.MESH | Recombinant Proteins/genetics | - |
dc.subject.MESH | Recombinant Proteins/metabolism | - |
dc.title | Analysis of hydrolyzable polyethylene glycol hydrogels and deproteinized bone mineral as delivery systems for glycosylated and non-glycosylated bone morphogenetic protein-2 | - |
dc.type | Article | - |
dc.contributor.college | College of Dentistry (치과대학) | - |
dc.contributor.department | Dept. of Periodontology (치주과학) | - |
dc.contributor.googleauthor | Patrick Hänseler | - |
dc.contributor.googleauthor | Ui-Won Jung | - |
dc.contributor.googleauthor | Ronald E. Jung | - |
dc.contributor.googleauthor | Kyoung-Hee Choi | - |
dc.contributor.googleauthor | Kyoo-Sung Cho | - |
dc.contributor.googleauthor | Christoph H.F | - |
dc.contributor.googleauthor | Hämmerle | - |
dc.contributor.googleauthor | Franz E. Webera | - |
dc.identifier.doi | 10.1016/j.actbio.2011.08.002 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03692 | - |
dc.contributor.localId | A03810 | - |
dc.relation.journalcode | J00007 | - |
dc.identifier.eissn | 1878-7568 | - |
dc.identifier.pmid | 21867781 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1742706111003461 | - |
dc.subject.keyword | Bone substitutes | - |
dc.subject.keyword | Recombinant rhBMP-2 protein | - |
dc.subject.keyword | Hydrogel | - |
dc.subject.keyword | Bio-Oss | - |
dc.subject.keyword | Drug delivery system | - |
dc.contributor.alternativeName | Jung, Ui Won | - |
dc.contributor.alternativeName | Cho, Kyoo Sung | - |
dc.contributor.affiliatedAuthor | Jung, Ui Won | - |
dc.contributor.affiliatedAuthor | Cho, Kyoo Sung | - |
dc.citation.volume | 8 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 116 | - |
dc.citation.endPage | 123 | - |
dc.identifier.bibliographicCitation | ACTA BIOMATERIALIA, Vol.8(1) : 116-123, 2012 | - |
dc.identifier.rimsid | 34552 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.